Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.71 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | FABP2 | P12104 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8755138 | 1.00 | APP (0.78) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL10704177 | 0.87 | APP (0.60) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL11499580 | 0.87 | APP (0.60) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL16024214 | 0.87 | APP (0.64) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL7325024 | 0.86 | APP (0.58) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL8754966 | 0.85 | APP (0.58) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL4201571 | 0.85 | APP (0.58) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL20516036 | 0.84 | APP (0.57) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL31612396 | 0.84 | APP (0.57) | APPAKR1C3AKR1C2CYP2C9CYP3A4 | |
| SCHEMBL2548793 | 0.83 | AKR1C3 (1.00) | APPAKR1C3AKR1C2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2017080989-A1 | (R)-FLURIPROFEN FOR THE PREVENTION AND/OR TREATMENT OF DIABETES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-05-18 | — | — | WO | disclosed |
| US-20150232407-A1 | DRUG SUBSTANCE PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS COMPRISING S-(+)-FLURBIPROFEN | AESICA PHARMACEUTICALS LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-02 | — | — | US | disclosed |
| WO-2014138343-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1587798-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | Merck & Co., Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2004064771-A2 | GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS | MERCK & CO., INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1201661-A1 | HETEROAROMATIC RING COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | APP 2522/4885AKR1C3 813/4885AKR1C2 517/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885AKR1C3 454/4885AKR1C2 787/4885 |
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | MMP17, NAALAD2, DNPEP | APP 2291/4885AKR1C3 436/4885AKR1C2 784/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 29/4885AKR1C3 484/4885AKR1C2 861/4885 |
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | CNR2, FAAH2, FAAH | APP 2009/4885AKR1C3 729/4885AKR1C2 821/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | APP 2/4885AKR1C3 1915/4885AKR1C2 2052/4885 |
| US-20150232407-A1 | DRUG SUBSTANCE PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS COMPRISING S-(+)-FLURBIPROFEN | CYP2F1, CYP2B6, GABBR2 | APP 1378/4885AKR1C3 565/4885AKR1C2 557/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885AKR1C3 454/4885AKR1C2 787/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | APP 2500/4885AKR1C3 2969/4885AKR1C2 2443/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | APP 8/4885AKR1C3 160/4885AKR1C2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.